These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Diagnostic value of diffusion-weighted imaging in simultaneous 18F-FDG PET/MR imaging for whole-body staging of women with pelvic malignancies. Grueneisen J; Schaarschmidt BM; Beiderwellen K; Schulze-Hagen A; Heubner M; Kinner S; Forsting M; Lauenstein T; Ruhlmann V; Umutlu L J Nucl Med; 2014 Dec; 55(12):1930-5. PubMed ID: 25453042 [TBL] [Abstract][Full Text] [Related]
5. 18F-FDG PET and CT/MRI in oral cavity squamous cell carcinoma: a prospective study of 124 patients with histologic correlation. Ng SH; Yen TC; Liao CT; Chang JT; Chan SC; Ko SF; Wang HM; Wong HF J Nucl Med; 2005 Jul; 46(7):1136-43. PubMed ID: 16000282 [TBL] [Abstract][Full Text] [Related]
6. Diffusion-weighted MR imaging in comparison to integrated [¹⁸F]-FDG PET/CT for N-staging in patients with lung cancer. Pauls S; Schmidt SA; Juchems MS; Klass O; Luster M; Reske SN; Brambs HJ; Feuerlein S Eur J Radiol; 2012 Jan; 81(1):178-82. PubMed ID: 20932700 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of diffusion-weighted MRI for pretherapeutic assessment and staging of lymphoma: results of a prospective study in 140 patients. Mayerhoefer ME; Karanikas G; Kletter K; Prosch H; Kiesewetter B; Skrabs C; Porpaczy E; Weber M; Pinker-Domenig K; Berzaczy D; Hoffmann M; Sillaber C; Jaeger U; Müllauer L; Simonitsch-Klupp I; Dolak W; Gaiger A; Ubl P; Lukas J; Raderer M Clin Cancer Res; 2014 Jun; 20(11):2984-93. PubMed ID: 24696320 [TBL] [Abstract][Full Text] [Related]
8. Diagnosis of peritoneal dissemination: comparison of 18F-FDG PET/CT, diffusion-weighted MRI, and contrast-enhanced MDCT. Satoh Y; Ichikawa T; Motosugi U; Kimura K; Sou H; Sano K; Araki T AJR Am J Roentgenol; 2011 Feb; 196(2):447-53. PubMed ID: 21257899 [TBL] [Abstract][Full Text] [Related]
11. Simulation of a MR-PET protocol for staging of head-and-neck cancer including Dixon MR for attenuation correction. Eiber M; Souvatzoglou M; Pickhard A; Loeffelbein DJ; Knopf A; Holzapfel K; Martinez-Möller A; Nekolla SG; Scherer EQ; Schwaiger M; Rummeny EJ; Beer AJ Eur J Radiol; 2012 Oct; 81(10):2658-65. PubMed ID: 22078793 [TBL] [Abstract][Full Text] [Related]
12. Detection of metastatic lesions from malignant pheochromocytoma and paraganglioma with diffusion-weighted magnetic resonance imaging: comparison with 18F-FDG positron emission tomography and 123I-MIBG scintigraphy. Takano A; Oriuchi N; Tsushima Y; Taketomi-Takahashi A; Nakajima T; Arisaka Y; Higuchi T; Amanuma M; Endo K Ann Nucl Med; 2008 Jun; 22(5):395-401. PubMed ID: 18600417 [TBL] [Abstract][Full Text] [Related]
13. Supplemental value of diffusion-weighted whole-body imaging with background body signal suppression (DWIBS) technique to whole-body magnetic resonance imaging in detection of bone metastases from thyroid cancer. Sakurai Y; Kawai H; Iwano S; Ito S; Ogawa H; Naganawa S J Med Imaging Radiat Oncol; 2013 Jun; 57(3):297-305. PubMed ID: 23721138 [TBL] [Abstract][Full Text] [Related]
14. Whole-body diffusion-weighted imaging: the added value to whole-body MRI at initial diagnosis of lymphoma. Gu J; Chan T; Zhang J; Leung AY; Kwong YL; Khong PL AJR Am J Roentgenol; 2011 Sep; 197(3):W384-91. PubMed ID: 21862763 [TBL] [Abstract][Full Text] [Related]
15. Whole-body diffusion-weighted imaging vs. FDG-PET for the detection of non-small-cell lung cancer. How do they measure up? Chen W; Jian W; Li HT; Li C; Zhang YK; Xie B; Zhou DQ; Dai YM; Lin Y; Lu M; Huang XQ; Xu CX; Chen L Magn Reson Imaging; 2010 Jun; 28(5):613-20. PubMed ID: 20418042 [TBL] [Abstract][Full Text] [Related]
16. Whole-body magnetic resonance imaging and positron emission tomography-computed tomography in oncology. Schmidt GP; Kramer H; Reiser MF; Glaser C Top Magn Reson Imaging; 2007 Jun; 18(3):193-202. PubMed ID: 17762383 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of PET and MR datasets in integrated 18F-FDG PET/MRI: A comparison of different MR sequences for whole-body restaging of breast cancer patients. Grueneisen J; Sawicki LM; Wetter A; Kirchner J; Kinner S; Aktas B; Forsting M; Ruhlmann V; Umutlu L Eur J Radiol; 2017 Apr; 89():14-19. PubMed ID: 28267530 [TBL] [Abstract][Full Text] [Related]
18. Integrated whole-body PET/MR hybrid imaging: clinical experience. Quick HH; von Gall C; Zeilinger M; Wiesmüller M; Braun H; Ziegler S; Kuwert T; Uder M; Dörfler A; Kalender WA; Lell M Invest Radiol; 2013 May; 48(5):280-9. PubMed ID: 23442775 [TBL] [Abstract][Full Text] [Related]
19. Diagnostic value of diffusion-weighted magnetic resonance imaging (DWI) compared to FDG PET/CT for whole-body breast cancer staging. Heusner TA; Kuemmel S; Koeninger A; Hamami ME; Hahn S; Quinsten A; Bockisch A; Forsting M; Lauenstein T; Antoch G; Stahl A Eur J Nucl Med Mol Imaging; 2010 Jun; 37(6):1077-86. PubMed ID: 20204355 [TBL] [Abstract][Full Text] [Related]
20. Feasibility of [18F]FDG-PET and coregistered CT on clinical target volume definition of advanced non-small cell lung cancer. Messa C; Ceresoli GL; Rizzo G; Artioli D; Cattaneo M; Castellone P; Gregorc V; Picchio M; Landoni C; Fazio F Q J Nucl Med Mol Imaging; 2005 Sep; 49(3):259-66. PubMed ID: 16172572 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]